Pharmaceutical Legislation of the European Union, Japan and the United States of America – An Overview

Barbara Jentges, PhD, Editor

Updated and Expanded Second Edition

- New Chapter on Post-Approval Changes
- New Chapter on CTD Regional Requirements
- Expanded Chapter on Drug Master Files

PDA®
Parenteral Drug Association

www.pda.org/bookstore

Pharmaceutical Legislation of the European Union, Japan and the United States of America – An Overview

Second Edition

Barbara Jentges, PhD, Editor

Parenteral Drug Association, Inc. – *Connecting People, Science and Regulation*, Bethesda, MD 20815

Second Edition 2016

23 22 21 20 19 18 17 16 1 2 3 4 5

ISBN: 978-0-939459-85-8

PDA has reprinted Table 2: Partial Changes to Approved Matters that Require Prior Approval and Table 3: Minor Changes to Approved Matters that Require Notification (Chapter 5) and Figure 1: Template of the Application Form, Table 1: Summary Table of Attachments, and Table 2: Table of Contents for Module 1 Administrative and Prescribing Information (Chapter 6) with permission of JIHO, Inc.

Foreword vi

Authors viii

Contributors from Edition 1 ix

Introduction 1

Chapter 1: **Pharmaceutical Legislation** 3
Introduction 4
A. Japan 4
1. Japanese Law (Japanese Constitution) and the Government 4
2. Japanese Pharmaceutical Law System 4
B. European Union 10
1. European Law and Institutions 10
2. EU Pharmaceutical Legislation: EudraLex 13
C. United States 15
1. U.S. Pharmaceutical Law and the U.S. Federal Government 15
2. U.S. Pharmaceutical Regulations 18
3. FDA Regulatory Guidance 19

Chapter 2: **Regulatory Bodies** 24
Introduction 25
A. Japan 25
1. Certification System for New Drugs (Approval Examination System) 28
B. European Union 28
1. Key Authorities for Licensing Medicinal Drug Product 29
C. United States 34
1. Functions of FDA Centers and Offices 34

Chapter 3: **Market Authorization and Licensing** 40
Introduction 41
A. Japan 42
1. Specific Features of the Japanese Market Approval Process for Drug Products 42
2. Steps Toward Manufacturing/Marketing Authorization 45
3. Orphan Drugs and Medical Devices 48
B. European Union 52
1. General Aspects of Marketing Authorization Applications and Approval 52
2. Overview of Procedures for Marketing Authorization Applications 54
3. Electronic Common Technical Document and Electronic Submission 60

C. United States 61
1. General Aspects of Marketing Authorization Application Review and Approval 61
2. NDA, ANDA, and BLA Procedures for Drugs and Biologic Products 69
3. Clearance Processes for Medical Device 72
4. Approval Process for Combination Products 74

Chapter 4: **Drug Master File Systems** 78
Introduction 79
A. Japan 80
1. Disclosed and Nondisclosed Information 81
2. DMF Registration by Foreign Manufacturers 81
B. Europe 83
1. Open and Closed Concept of the European Union Active Substance Master File 83
2. ASMF Dossier – Structure and Content 83
3. Formal and Procedural Aspects 85
4. Steps toward Facilitating the ASMF Procedure 87
5. The Vision — A Concept Towards an Internationally Harmonized Drug Master File System 89
C. United States 90
1. Purpose and Scope of a Drug Master File 91
2. GDUFA Fees for Certain Type II DMFs 93
3. Initial DMF Content, Format, and Submission Process 95
4. DMF Amendments, Annual Updates, and Ownership Transfers 98
5. Process for Drug Applications to Incorporate by Reference an Active DMF 99

Chapter 5: **Post-Approval Changes** 102
Introduction 103
A. Japan 105
1. Application for Changes to Approved Matters 105
2. Quality by Design and Design Space 108
B. European Union 109
1. Classification of Post-Approval Changes 109
2. New Concepts to Enhance Regulatory Flexibility 111
3. Grouping of Changes and Worksharing Procedure 113
4. Variations Application Form 114
C. United States 114
1. Classification of Post-Approval Changes for Drug and Biological Products 115

Chapter 6: **Regional Administrative Requirements For Module 1** 121
Introduction 122
A. Japan 122
1. Description of the Japanese Application Form 125
2. Part 1 of the Japanese CTD 127
B. European Union 128
1. Module 1 of the European Union CTD 128
2. Brief Reflection on Selected Items of EU Module 1 131
C. United States 133
1. Part 1 of the U.S. CTD 133

Acronyms 141

Index 144

Figures and Tables

Chapter 1: **Pharmaceutical Legislation**

Figure 1 High-Level Structure of Japan's Government 5
Figure 2 Law System of Japanese Pharmaceutical Regulation 6
Table 1 Examples of Significant Cabinet Orders—Japan 7
Table 2 Examples of Significant Ministerial Ordinances—Japan 8
Table 3 Other Regulatory Guidance Examples — Japan 9
Figure 3 High-Level Structure of the EU Institutions, Bodies, and Agencies 12
Figure 4 EU Pharmaceutical Legislation for Medicinal Products for Human Use and Veterinary Use (EudraLex) 14
Figure 5 High-Level Structure of the U.S. Federal Government and the Food and Drug Administration 16
Table 4 Key Pharmaceutical Laws Enacted Following the FD&C Act 17
Figure 6 U.S. Pharmaceutical Law System 18

Chapter 2: **Regulatory Bodies**

Figure 1 Regulatory Bodies in Japan 26
Table 1 Key Services of PMDA 27
Table 2 Inspection Authorities: PMDA and Prefecture 28
Figure 2 European Medicines Agency – A European Union Decentralised Agency 31
Figure 3 National and Supranational Regulatory Bodies in Different EU Marketing Authorization Procedures 33
Figure 4 Overview of U.S. Food and Drug Administration Organization 37

Chapter 3: **Market Authorization and Licensing**

Figure 1 ICH CTD Triangle 41
Figure 2 Interrelated Manufacturing and Marketing Approval System in Japan 43
Figure 3 Manufacturing/Marketing Triumvirate High Level View of Responsibilities 45
Figure 4 Examinations in Accreditation for Foreign Manufacturers 47
Figure 5 Flowchart of Review Process (Japan) 49
Figure 6 Flow for Issuance of Foreign Manufacturer GMP Inspection (Application by MAH) 50
Figure 7 Flow for Issuance of Foreign Manufacturer GMP Inspection (Application by the Representative) 51
Figure 8 Procedures for Marketing Authorization Applications in the European Union 53
Figure 9 Timelines for the Centralized Procedure 57
Figure 10 FDA Review Process 62
Figure 11 CDER Overall NME NDA/BLAs Median Total Time to Approval 67
Figure 12 NDA/ANDA/BLA Review Process 71
Figure 13 Process for Clearance of a New Device 73

Chapter 4: **Drug Master File Systems**

Figure 1 Master File Approval System for Drug Product in Japan 80
Table 1 Master File Pharmaceutical Registration Items Submitted in CTD Module 3 82
Table 2 Resources for Submitting the DMF 83
Figure 2 Components of an ASMF (components of the ASMF RP marked in red) 86
Table 3 EMEA and EU ASMF Numbers – What is What? 89

Chapter 5: **Post-Approval Changes**

Table 1 Categories of Changes in Japan, EU, and U.S. 104
Figure 1 Precategorization and Marking of Partial and Minor Changes in the Manufacturing Method Column of the (initial) M/M-AF 105
Table 2 Partial Changes to Approved Matters that Require Prior Approval 107
Table 3 Minor Changes to Approved Matters that Require Notification 108
Table 4 Categories of Post-Approval Changes According to Commission Regulation (EC) No. 1234/2008 110

Chapter 6: **Regional Administrative Requirements For Module 1**

Figure 1 Template of the Application Form 123
Table 1 Summary Table of Attachments 124
Figure 2 Allocation of Columns in the Japanese Application Form with the Sections in CTD Module 3 (Quality Drug Substance, 3.2.S and Quality Drug Product 3.2.P) 125
Figure 3 Example of Symbols and Description 126
Table 2 Table of Contents for Module 1 Administrative and Prescribing Information 127
Table 3 Table of Contents for EU Module 1 Administrative and Prescribing Information 128
Table 4 Table of Contents for U.S. Module 1 Administrative Information 134